ArticleCureus2026
Validation of the International Academy of Cytology Yokohama System for Reporting Breast Fine-Needle Aspiration Cytopathology.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background The International Academy of Cytology (IAC) Yokohama System for the classification of fine-needle aspiration cytology (FNAC) is a diagnostic tool for breast lumps. Cyto-histopathological correlation increases diagnostic precision and is of great relevance. Aim To classify the FNAC of breast lesions according to the IAC Yokohama classification system and to study sensitivity, specificity, and risk of malignancy (ROM) by correlating with histopathological examination. Settings and design A three-year retrospective study of 63 breast FNAC cases with histopathological correlation was performed using the Yokohama System. Materials and methods Taking histopathological diagnosis as the gold standard, diagnostic indices, including sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV), were evaluated. The 63 cases were subsequently recategorized according to the Yokohama System into the following categories: insufficient, benign, atypical, suspicious for malignancy, and malignant. Results The ROM across the Yokohama categories was 0% in Category 1 (insufficient), 1.92% in Category 2 (benign), 33.3% in Category 3 (atypical), and 100% in both Category 4 (suspicious for malignancy) and Category 5 (malignant). When malignant cases were considered positive, the diagnostic performance showed a sensitivity of 87.5%, specificity of 96.4%, PPV of 77.7%, and NPV of 98%. Conclusion The recategorization based on the IAC Yokohama System successfully classifies breast lesions according to their ROM and offers direction for the management strategy of each category. The adoption of the IAC Yokohama System for breast cytopathology reporting, with its standardized terminology, ensures improved diagnostic clarity, consistency, and accuracy, while also facilitating better prediction of the ROM and guiding clinical management and patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.